Back to Clinical Trial Search

Clinical Trial

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma

Cancer Type

Head & Neck

Protocol Number

202508139

Principal Investigator

Adkins, Douglas

Learn more about this study at clinicaltrials.gov

For more information contact us here:

Phone

800-600-3606

Email

[email protected]

Brief Summary

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

Protocol Interventions

Drug: Pembrolizumab
Learn About Clinical Trials

Clinical trials are research studies that help us find new ways to prevent, diagnose, and treat cancer. If you are interested in participating in a clinical trial, our team will help you find a study that is right for you. Call us to speak with a Siteman care coordinator.

Call Us Refer a Patient